| Golden Living Center-muncie | |
| 2701 Lyn-mar Dr, Muncie, Indiana 47304 | |
| (765) 286-5979 | |
| Name | Golden Living Center-muncie |
|---|---|
| Location | 2701 Lyn-mar Dr, Muncie, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 117 |
| Occupancy Rate | 84.36% |
| Medicare ID (CCN) | 155687 |
| Legal Business Name | Hendricks County Hospital |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1063682896 |
| Organization Name | HENDRICKS COUNTY HOSPITAL |
| Doing Business As | BRICKYARD HEALTHCARE - MUNCIE CARE CENTER |
| Address | 2701 N Lyn Mar Dr, Muncie, IN 47304 |
| Phone Number | 765-286-5979 |
News Archive
At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.
If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.
In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.
With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.
› Verified 2 days ago
| NPI Number | 1851835037 |
| Organization Name | DYCORA TRANSITIONAL HEALTH - MUNCIE LLC |
| Address | 2701 N Lyn Mar Dr, Muncie, IN 47304 |
| Phone Number | 765-286-5979 |
News Archive
At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.
If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.
In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.
With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.
If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.
In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.
With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $8775 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.53 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.36 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 64.52 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.62 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 9.71 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.31 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.02 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 34.63 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 5.81 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 6.35 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.41 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.52 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.06 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 100 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 57.69 | 82.93 |
News Archive
At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.
If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.
In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.
With the nation collectively spending about $18 billion per year on osteoporosis related bone fractures, Geisinger researchers found that streamlining the ordering process for osteoporosis bone density scans quadrupled the number of patients who received the exam.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.
› Verified 2 days ago
Westminster Village Muncie Inc Location: 5801 W Bethel Ave, Muncie, Indiana 47304 Phone: (765) 288-2155 | |
Signature Healthcare Of Muncie Location: 4301 N Walnut St, Muncie, Indiana 47303 Phone: (765) 282-0053 | |